Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Caralluma fimbriata
Succulente comestible originaire d'Inde utilisée par les tribus comme coupe-faim lors des famines, maintenant étudiée pour la gestion du poids et le diabète.
Caralluma fimbriata is a succulent plant native to India, traditionally used by tribal populations as an appetite suppressant during famine and for endurance. Modern research focuses on its potential for weight management and antidiabetic effects, attributed primarily to pregnane glycosides and flavonoids. It is classified as evidence level C, indicating limited or preliminary clinical data.
Pregnane glycosides in Caralluma fimbriata are thought to inhibit citrate lyase, reducing fatty acid synthesis and promoting appetite suppression via AMPK activation in the hypothalamus. Additionally, these compounds may enhance glucose uptake in peripheral tissues by modulating GLUT4 translocation and improving insulin sensitivity. Flavonoids contribute antioxidant and anti-inflammatory effects, potentially supporting metabolic health.
Succulente comestible originaire d'Inde utilisée par les tribus comme coupe-faim lors des famines, maintenant étudiée pour la gestion du poids et le diabète.
Caralluma fimbriata is a succulent plant native to India, traditionally used by tribal populations as an appetite suppressant during famine and for endurance. Modern research focuses on its potential for weight management and antidiabetic effects, attributed primarily to pregnane glycosides and flavonoids. It is classified as evidence level C, indicating limited or preliminary clinical data.
Pregnane glycosides in Caralluma fimbriata are thought to inhibit citrate lyase, reducing fatty acid synthesis and promoting appetite suppression via AMPK activation in the hypothalamus. Additionally, these compounds may enhance glucose uptake in peripheral tissues by modulating GLUT4 translocation and improving insulin sensitivity. Flavonoids contribute antioxidant and anti-inflammatory effects, potentially supporting metabolic health.